Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04149002 · ClinicalTrials.gov registry record · NA

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

A NA study, sponsored by Duke University.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT04149002: Completed NA study, sponsored by Duke University.

NCT04149002 is a NA study that has completed, run by Duke University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04149002, a NA study, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this study is to pilot an intervention that was developed to improve uptake and adhere to an Individualized Prematurity Prevention Plan (IP3) for preterm birth prevention. Non-Hispanic Black (NHB) women are at higher risk for preterm birth compared to other racial and ethnic groups. Building on qualitative data from NHB women with input from a multidisciplinary stakeholder group, a patient-centered intervention was developed to improve uptake and adherence to an IP3 in NHB women.

Primary Outcome

Enrollment target of 30% of eligible patients recruited.

Interventions

  • BEHAVIORAL Intervention Arm Weekly IP3 text messages
  • OTHER Active Control Arm General pregnancy text messages

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-02-01
Est. Completion 2021-04-01
Phase NA
Duke University

1,725 total trials

What the finished NCT04149002 record still lists

NCT04149002 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Intervention Arm Weekly IP3 text messages is the first listed.

NCT04149002 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04149002 about?

NCT04149002 is a clinical study titled "Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan". The purpose of this study is to pilot an intervention that was developed to improve uptake and adhere to an Individualized Prematurity Prevention Plan (IP3) for preterm birth prevention. Non-Hispanic Black (NHB) women are at higher risk for preterm birth compared to other racial and ethnic groups. B...

What is the current status of trial NCT04149002?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2020-02-01. Estimated completion is 2021-04-01.

What interventions are being tested in trial NCT04149002?

The interventions under investigation include: Intervention Arm Weekly IP3 text messages (BEHAVIORAL), Active Control Arm General pregnancy text messages (OTHER).

Who is sponsoring clinical trial NCT04149002?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04149002's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04149002, the US trial registry maintained by the National Library of Medicine. NCT04149002 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.